These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 28270496)
1. Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. Zhou F; Pan Y; Wei Y; Zhang R; Bai G; Shen Q; Meng S; Le XF; Andreeff M; Claret FX Clin Cancer Res; 2017 Aug; 23(15):4450-4461. PubMed ID: 28270496 [No Abstract] [Full Text] [Related]
2. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression. Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252 [TBL] [Abstract][Full Text] [Related]
4. Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway. Zhu Y; Qiu Z; Zhang X; Qian F; Wang B; Wang L; Shi H; Yu R J Neurooncol; 2017 Jan; 131(1):31-39. PubMed ID: 27640199 [TBL] [Abstract][Full Text] [Related]
5. Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome. Pandey P; Siddiqui MH; Behari A; Kapoor VK; Mishra K; Sayyed U; Tiwari RK; Shekh R; Bajpai P Anticancer Agents Med Chem; 2019; 19(16):2019-2033. PubMed ID: 31345154 [TBL] [Abstract][Full Text] [Related]
6. Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5. Wang S; Pan Y; Zhang R; Xu T; Wu W; Zhang R; Wang C; Huang H; Calin CA; Yang H; Claret FX Oncogene; 2016 Nov; 35(47):6096-6108. PubMed ID: 27157611 [TBL] [Abstract][Full Text] [Related]
7. Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. Hwang CY; Ryu YS; Chung MS; Kim KD; Park SS; Chae SK; Chae HZ; Kwon KS Oncogene; 2004 Nov; 23(55):8868-75. PubMed ID: 15480426 [TBL] [Abstract][Full Text] [Related]
8. Jab1/Cops5: a promising target for cancer diagnosis and therapy. Yuan C; Wang D; Liu G; Pan Y Int J Clin Oncol; 2021 Jul; 26(7):1159-1169. PubMed ID: 34019195 [TBL] [Abstract][Full Text] [Related]
9. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer. Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449 [TBL] [Abstract][Full Text] [Related]
10. JAB1/COPS5 is a putative oncogene that controls critical oncoproteins deregulated in prostate cancer. Danielpour D; Purighalla S; Wang E; Zmina PM; Sarkar A; Zhou G Biochem Biophys Res Commun; 2019 Oct; 518(2):374-380. PubMed ID: 31434609 [TBL] [Abstract][Full Text] [Related]
11. CSN5/JAB1 suppresses the WNT inhibitor DKK1 in colorectal cancer cells. Jumpertz S; Hennes T; Asare Y; Schütz AK; Bernhagen J Cell Signal; 2017 Jun; 34():38-46. PubMed ID: 28229932 [TBL] [Abstract][Full Text] [Related]
12. Let-7d Inhibits Growth and Metastasis in Breast Cancer by Targeting Jab1/Cops5. Wei Y; Liu G; Wu B; Yuan Y; Pan Y Cell Physiol Biochem; 2018; 47(5):2126-2135. PubMed ID: 29975923 [TBL] [Abstract][Full Text] [Related]
13. α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer. Chen X; Jia Y; Zhang Y; Zhou D; Sun H; Ma X J Cell Mol Med; 2020 Feb; 24(4):2497-2506. PubMed ID: 31930655 [TBL] [Abstract][Full Text] [Related]
14. Elucidation of the Chemopreventive Role of Stigmasterol Against Jab1 in Gall Bladder Carcinoma. Pandey P; Bajpai P; Siddiqui MH; Sayyed U; Tiwari R; Shekh R; Mishra K; Kapoor VK Endocr Metab Immune Disord Drug Targets; 2019; 19(6):826-837. PubMed ID: 30727937 [TBL] [Abstract][Full Text] [Related]
15. COPS5 and LASP1 synergistically interact to downregulate 14-3-3σ expression and promote colorectal cancer progression via activating PI3K/AKT pathway. Zhou R; Shao Z; Liu J; Zhan W; Gao Q; Pan Z; Wu L; Xu L; Ding Y; Zhao L Int J Cancer; 2018 May; 142(9):1853-1864. PubMed ID: 29226323 [TBL] [Abstract][Full Text] [Related]
16. Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51. Liu G; Yu M; Wu B; Guo S; Huang X; Zhou F; Claret FX; Pan Y Cell Signal; 2019 Jan; 53():39-48. PubMed ID: 30244171 [TBL] [Abstract][Full Text] [Related]
17. JAB1/CSN5 and the COP9 signalosome. A complex situation. Chamovitz DA; Segal D EMBO Rep; 2001 Feb; 2(2):96-101. PubMed ID: 11258719 [TBL] [Abstract][Full Text] [Related]
18. The emerging roles of Jab1/CSN5 in cancer. Wang L; Zheng JN; Pei DS Med Oncol; 2016 Aug; 33(8):90. PubMed ID: 27412572 [TBL] [Abstract][Full Text] [Related]
19. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. Hsu MC; Chang HC; Hung WC Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096 [TBL] [Abstract][Full Text] [Related]
20. X-linked intellectual disability gene CUL4B targets Jab1/CSN5 for degradation and regulates bone morphogenetic protein signaling. He F; Lu D; Jiang B; Wang Y; Liu Q; Liu Q; Shao C; Li X; Gong Y Biochim Biophys Acta; 2013 May; 1832(5):595-605. PubMed ID: 23357576 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]